Ronald E. DeGryse

OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Results From the Double‐Blind, Randomized, Placebo‐Controlled Phases of the PREEMPT Clinical Program

David W. Dodick, Catherine C. Turkel, Ronald E. DeGryse et al. · Headache The Journal of Head and Face Pain · 2010 · 986 citations

Medicine, Pharmacology, Pharmacotherapy +17

OnabotulinumtoxinA for Treatment of Chronic Migraine: Pooled Analyses of the 56‐Week PREEMPT Clinical Program

Sheena K. Aurora, Paul Winner, Marshall C. Freeman et al. · Headache The Journal of Head and Face Pain · 2011 · 300 citations

Medicine, Pharmacology, Pharmacotherapy +17

Botulinum Toxin Type A for the Prophylaxis of Chronic Daily Headache: Subgroup Analysis of Patients Not Receiving Other Prophylactic Medications: A Randomized Double‐Blind, Placebo‐Controlled Study

David W. Dodick, Alexander Mauskop, Arthur H. Elkind et al. · Headache The Journal of Head and Face Pain · 2005 · 222 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +17

OnabotulinumtoxinA for treatment of chronic migraine: PREEMPT 24-week pooled subgroup analysis of patients who had acute headache medication overuse at baseline

Stephen D. Silberstein, Andrew Blumenfeld, Roger Cady et al. · Journal of the Neurological Sciences · 2013 · 215 citations

Pharmacy, Pharmacology, Pharmacotherapy +13

Botulinum Toxin Type A for the Prophylactic Treatment of Chronic Daily Headache: A Randomized, Double-Blind, Placebo-Controlled Trial

Stephen D. Silberstein, Stuart R. Stark, Sylvia Lucas et al. · Mayo Clinic Proceedings · 2005 · 178 citations

Medicine, Neurology, Pharmacotherapy +13